Preparation of rifampicin/poly(d,l-lactice) nanoparticles for sustained release by supercritical assisted atomization technique
No Thumbnail Available
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Abstract
Description
Research Article published by Elsevier Volume 95
In this work supercritical assisted atomization (SAA) process was used for the co-precipitation of poly(d,l-lactide) (PDLLA) and rifampicin (RIF) as nanoparticles for sustained release applications. The effect of the variation of PDLLA/RIF ratio on co-precipitate characteristics was mainly investigated. The precipitated particles were analyzed in terms of their morphological, thermodynamic and crystallographic properties. In addition, loading efficiency and in-vitro release studies were conducted. Spherical PDLLA/RIF nanoparticles with mean diameter ranging from 123 to 148 nm were prepared. Loading efficiency was greater than 100% resulting in RIF loadings of 28.8 to 50.5%. X-ray diffraction revealed that the encapsulated RIF is in an amorphous state, while NMR spectra indicated no structural modifications after the SAA process. In-vitro release studies showed an initial burst release of 80–87% of total RIF loaded, necessary to suppress the generation of resistance by the microorganism, followed by first-order sustained release between 0.4 and 0.8 mg/L RIF per day over a period of 17 days.
In this work supercritical assisted atomization (SAA) process was used for the co-precipitation of poly(d,l-lactide) (PDLLA) and rifampicin (RIF) as nanoparticles for sustained release applications. The effect of the variation of PDLLA/RIF ratio on co-precipitate characteristics was mainly investigated. The precipitated particles were analyzed in terms of their morphological, thermodynamic and crystallographic properties. In addition, loading efficiency and in-vitro release studies were conducted. Spherical PDLLA/RIF nanoparticles with mean diameter ranging from 123 to 148 nm were prepared. Loading efficiency was greater than 100% resulting in RIF loadings of 28.8 to 50.5%. X-ray diffraction revealed that the encapsulated RIF is in an amorphous state, while NMR spectra indicated no structural modifications after the SAA process. In-vitro release studies showed an initial burst release of 80–87% of total RIF loaded, necessary to suppress the generation of resistance by the microorganism, followed by first-order sustained release between 0.4 and 0.8 mg/L RIF per day over a period of 17 days.
Keywords
Supercritical assisted atomization (SAA), Nano-encapsulation